re viability comparisons- our capex, IRR isnt dissimilar to above projects, our NPV is materially lower however, (but still acceptable), which is generating lack of buyers.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025